Sunflower Meal and Supplementation of an Enzyme Complex in Layer Diets

ABSTRACTThe objective of this experiment was to evaluate the performance of 64- to 79-wk-old laying hens fed diets supplemented with an enzyme complex (EC) and containing increasing sunflower meal (SFM) levels. A total of 384 Hy-Line Brown layers were distributed according to a randomized block design in a 4 × 2 factorial arrangement (four levels of SFM, and inclusion or not of EC), with eight replicates of six birds each unit. The levels of SFM inclusion were 0, 8, 16 and 24%, utilized in two distinct diets. Diets were calculated to meet all the nutritional requirements of birds, except for the nutrients that would be made available by the nutritional matrix of the enzyme complex, with or without utilization of EC. The parameters analyzed were feed intake (g/bird/day), egg production (%/bird/day), egg weight, egg mass (g/bird/day), feed conversion ratio per egg mass, feed conversion ratio per dozen eggs, body weight gain, egg components (yolk, albumen and eggshell) and the economic efficiency index (EEI). There was no interaction between EC addition and the SFM levels in the diet. The addition of EC in the diets of laying hens did not affect egg productive or components parameters. The increase in the SFM levels in the diet presented quadratic effect on egg production and feed conversion ratio per dozen eggs, with calculated optimal sunflower meal inclusion levels of 6.72% and 5.83%, respectively, for each parameter. The best economic efficiency per dozen eggs was obtained with the diet with 16.0% SFM and EC inclusion, whereas per egg mass with the diet with of 24.0% SFM and no EC addition

Hemangioma colorretal Colon rectal hemangioma

O hemangioma colorretal (HCR) é uma lesão vascular benigna rara, com manifestação clínica geralmente entre 5 e 25 anos de idade. Faz parte do diagnóstico diferencial das causas de hemorragia digestiva baixa, sendo confundido, na maioria das vezes, com entidades mais comuns, como hemorróidas e doenças inflamatórias intestinais. O retardo do diagnóstico ocorre freqüentemente devido ao desconhecimento da doença, com taxas de mortalidade alcançando 40 a 50% na presença de sangramento importante. O caso relatado é de uma paciente de 17 anos de idade, admitida no Serviço de Colo-proctologia do Hospital Universitário - HUUFMA, em setembro de 2005, com anemia e sangramento retal, desde a infância, de forma intermitente e não dolorosa. Apresentado sua história clínica e propedêutica diagnóstica, realizada por meio de exames laboratoriais, endoscopia digestiva alta, colonoscopia e arteriografia de mesentéricas e ilíacas internas. O tratamento cirúrgico realizado foi retossigmoidectomia convencional com anastomose colorretal baixa, com boa evolução pós-operatória, tendo o exame histopatológico da peça cirúrgica ressecada, confirmado o diagnostico.<br>The colon and rectum hemangioma is a rare benign vascular lesion, with clinical features usually between 5 and 25 years of age. It is included in the differential diagnose of the lower digestive bleeding causes, and has been frequently misdiagnosed with other more common entities, like hemorrhoids and bowel inflammatory disease. The late diagnose occurs usually because of the rarity of the disease, with mortality rates reaching 40 to 50% in presence of severe bleeding. We report a case of a 17 years old girl who was admitted at the Coloproctology Service of the Academic Hospital - HUUFMA, in September 2005, with anemia and intermittent rectal bleeding since childhood. Laboratorial findings included laboratorial exams, GI endoscopy, colonoscopy and arteriography of mesenteric and internal iliacs arteries. Conventional rectosigmoidectomy with low colorectal anastomosis was done, with good postoperative evolution and histopathologic examination of the resected specimen

Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance

In the 1990s, the application of immunotherapy approaches to target cancer cells resulted in significant clinical responses in patients with advanced malignancies who were refractory to conventional therapies. While early immunotherapeutics were focused on T cell-mediated cytotoxic activity, subsequent efforts were centered on targeted antibody-mediated anticancer therapy. The initial success with antibody therapy encouraged further studies and, consequently, there are now more than 25 FDA-approved antibodies directed against a range of targets. Although both T cell and antibody therapies continue to result in significant clinical responses with minimal toxicity, a significant subset of patients does not respond to immunotherapy and another subset develops resistance following an initial response. This review is focused on describing examples showing that cancer resistance to immunotherapies indeed occurs. In addition, it reviews the mechanisms being used to overcome the resistance to immunotherapies by targeting the tumor cell directly and/or the tumor microenvironment